BioMarin Pharmaceutical Inc. - Common Stock (BMRN) stock analysis

BMRN · BioMarin Pharmaceutical Inc. - Common Stock

Latest recorded price: USD 57.99

Model-estimated fair value: USD 6.40. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Biotechnology

At $57.99, BMRN trades 806.2% above the model's base-case value of $6.40. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $0.32 in the conservative case and $13.79 in the optimistic case, with a valuation confidence score of 55/100. About 74% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 15.4%, free cash flow margin 22.5%, ROIC 3.4%. The model does not flag any risk signals for this company.

Similar companies in Healthcare